Kyoto Pharmaceutical Industries, Ltd.

The Green Cross Corporation

Akihisa Yoshimi

Hiroaki Shirahase

Masayasu Kasai

Hiroshi Matsui

Hideo Kobayashi

Satoru Azukizawa

Shohei Nakamura

Fumio Fukata

Mamoru Kanda

Masahiro Kikuchi

Nobuharu Kakeya

Koichi Yamanouchi

Ken-ichi Nishimura

Takeshi Uchida

Nobuo Kondoh

Takayoshi Mori

Hideki Okunishi

Miho Ikai

Kenji Takahash

Tadatsugu Tarumi

Shouji Kamiya

Yuta Kobayashi

The novel heterocyclic compound of the present invention is a novel heterocyclic compound having the formula (I) Y: R&#x2014;C(R)&#x2550;N&#x2014;O&#x2014;wherein Ris H or Calkyl, Ris H, &#x2014;CO&#x2014;C(R)&#x2550;C(R)&#x2014;Rwherein Ris H or Calkyl, and Ris Calkyl, Calkenyl and the like, and the like, Y is the following group wherein X is O or S, Ris the same as R, Ris R&#x2014;C(R)&#x2550;C(R)&#x2014; wherein Ris the same as R, Ris Calkyl and the like, and the like, Ris the same as R, and Ris aryl and the like, Y&#x2014;(CH)n-O&#x2014; is bonded to the 6- or 7-position of the tetrahydroisoquinoline skeleton, and n is an integer of 1 to 4, or a pharmaceutically acceptable salt thereof. The compound (I) of the present invention is useful as a hypoglycemic agent, a hypolipidemic agent, an insulin resistance improver, a therapeutic agent of diabetes, a therapeutic agent of diabetic complications, a glucose tolerance improver, an anti-arteriosclerosis agent, an anti-obesity agent, an antiinflammatory agent, an agent for the prophylaxis or treatment of PPAR-mediated diseases or an agent for the prophylaxis or treatment of syndrome X.

Heterocyclic compound and medicinal use thereof

The present invention provides an indoline compound represented by the formula (I) wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing this indoline compound or a pharmaceutically acceptable salt thereof. The compound of the present invention shows superior ACAT inhibitory effect and superior lipoperoxidation inhibitory effect and is useful as an ACAT inhibitor or a lipoperoxidation inhibitor.

Indoline compound and medicinal use thereof

The novel heterocyclic derivative of the present invention is a novel heterocyclic derivative having the formula (I')wherein Ris a hydrogen atom or Calkyl, Ris &#x2014;CO&#x2014;C(R)&#x2550;C(R)&#x2014;Rwherein Ris a hydrogen atom or Calkyl, and Ris Calkyl, Calkenyl, aryl or aromatic heterocycle, &#x2014;CO&#x2014;C&#x2261;C&#x2014;Rwherein Ris Calkyl and the like, Ris a hydrogen atom or Calkyl, X is an oxygen atom or a sulfur atom, Ris optionally substituted phenyl, and n is an integer of 1 to 4, or a pharmaceutically acceptable salt thereof. The compound (I&#x2032;) of the present invention is useful as a hypoglycemic agent, a hypolipidemic agent, an insulin resistance improver, a therapeutic agent of diabetes, a therapeutic agent of diabetic complications, a glucose tolerance improver, an anti-arteriosclerosis agent, an anti-obesity agent, an antiinflammatory agent, an agent for the prophylaxis or treatment of PPAR-mediated diseases and an agent for the prophylaxis or treatment of syndrome X.

Heterocyclic derivatives and medicinal use thereof

Heterocyclic compounds and salts thereof and medicinal use of the same

The cromoglycic acid compound of the formula (I)

Medicinal use of cromoglycic acid compounds

A therapeutic agent for allergic dermatitis caused by type IV allergic reaction, which contains diethyl L-lysylcromoglycate of the formula:

Therapeutic agent for allergic dermatitis

Antirheumatic agent

Pharmaceutical preparation containing prostaglandin compound for rectal

Growing community of inventors

Takatsuki, Japan

Akihisa Yoshimi